Deepverge PLC Result of Broker Offer; Total Voting Rights (9682E)
November 01 2022 - 11:56AM
UK Regulatory
TIDMDVRG
RNS Number : 9682E
Deepverge PLC
01 November 2022
1 November 2022
DeepVerge PLC
("DeepVerge" or "Company")
Result of Broker Offer; Total Voting Rights
DeepVerge (AIM: DVRG), the environmental and life science group
of companies that develops and applies AI and IoT technology to
analytical instruments for the analysis and identification of
bacteria, virus and toxins, announces that, further to the
announcement made on 27 October 2022, the Broker Offer, a facility
to allow existing shareholders and other interested parties to
participate in the Fundraise on the same terms to the Placing
announced, has now closed having raised a gross amount of GBP0.815
million. The Company received interest of approximately GBP1
million which was scaled back to give priority to existing
shareholders.
Subject to approval at the General Meeting to be held on 14
November 2022, a total of 40,750,000 ordinary shares of 0.1p
nominal value each ("Broker Offer shares") will be allotted
conditional only on Third Admission with investors at 2p per share,
the same price as the Placing announced on 27 October 2022. Each
Broker Offer Share will rank pari passu with existing Ordinary
Shares. One Placing Warrant will be issued for every 4 Broker Offer
Shares successfully subscribed.
Application will be made for admission of the 40,750,000 Broker
Option Shares which will rank pari passu with existing Ordinary
Shares to trading on AIM ("Third Admission"), with Third Admission
expected to be on or around 16 November 2022.
Total Voting Rights
Following First Admission (which took place at 800am on 1
November 2022), the Company's issued share capital now consists of
252,662,334 shares with a nominal value of 0.1p each, with voting
rights ("Ordinary Shares").
Following Second Admission (expected 15 November 2022, subject
to the Resolutions being approved by Shareholders at the General
Meeting scheduled for 14 November 2022 ("General Meeting")), the
Company's issued share capital will consist of 387,662,334 Ordinary
Shares.
Following Third Admission (expected 16 November 2022, subject to
the Resolutions being approved by Shareholders at the General
Meeting) the Company's issued share capital will consist of
760,456,378 Ordinary Shares.
The Company does not hold any Ordinary Shares in Treasury.
Therefore, following each respective Admission, the above figure
may be used by shareholders in the Company as the denominator for
the calculation by which they will determine if they are required
to notify their interest in, or a change to their interest in, the
share capital of the Company under the FCA's Disclosure Guidance
and Transparency Rules.
Terms and definitions in this notification are as defined in the
notification of 27 October 2022.
Dr Nigel Burton, Interim CEO, commented: "The Company and Board
are grateful for the continued support of our shareholders in
challenging markets. With a strengthened balance sheet, the Company
can focus on leveraging its unique range of technologies to build
on its strong customer base, accelerate the continued expansion of
the business and deliver profitable growth and value for all our
shareholders."
For further information, please contact:
Enquiries:
Nigel Burton, Interim
DeepVerge plc Chief Executive +44 7785 234447
SPARK Advisory Partners
Limited
(Nominated Adviser) Neil Baldwin +44 (0) 113 370 8974
Turner Pope Investments
(TPI) Limited Andy Thacker/James
(Broker) Pope +44 (0) 20 3657 0050
Market Abuse Regulation (MAR) Disclosure
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED
UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014
WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL)
ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A
REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO
BE IN THE PUBLIC DOMAIN.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBUBDBDUGDGDB
(END) Dow Jones Newswires
November 01, 2022 11:56 ET (15:56 GMT)
Integumen (LSE:SKIN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Integumen (LSE:SKIN)
Historical Stock Chart
From Aug 2023 to Aug 2024